{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:34Z","timestamp":1786112794525,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing intestinal inflammation and substantial impairment of quality of life. Janus kinase (JAK) inhibitors are orally administered small-molecule agents that interfere with intracellular cytokine signaling pathways central to UC pathogenesis. This systematic review and meta-analysis aimed to assess the therapeutic benefits and safety profile of JAK inhibitors in adults with moderate-to-severe UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A systematic literature search was conducted in PubMed (from inception to November 2025), Embase, the Cochrane Library, and Web of Science to identify placebo-controlled RCTs evaluating JAK inhibitors in adult patients with UC. The primary efficacy outcomes were clinical remission and clinical response. Secondary outcomes included endoscopic remission, endoscopic response, and mucosal healing. Safety was assessed by the incidence of any adverse events (AEs). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models as appropriate. Statistical heterogeneity was evaluated using the\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic, and subgroup analyses were performed according to treatment phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Nine publications encompassing 14 placebo-controlled RCT datasets met the inclusion criteria. Compared with placebo, JAK inhibitors significantly increased rates of clinical remission (RR\u2005=\u20052.48, 95% CI: 1.64\u20133.73) and clinical response (RR\u2005=\u20052.53, 95% CI: 1.73\u20133.70), although moderate-to-high heterogeneity was observed. Endoscopic outcomes were also markedly improved, with higher rates of endoscopic remission (RR\u2005=\u20053.52, 95% CI: 2.55\u20134.86) and mucosal healing (RR\u2005=\u20052.60\u20132.79 across models). Safety analyses demonstrated no significant difference in the overall incidence of adverse events between JAK inhibitors and placebo. Subgroup analyses revealed consistent efficacy during both induction and maintenance phases, with comparable safety profiles across treatment periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>JAK inhibitors provide significant improvements in both clinical and endoscopic outcomes for patients with moderate-to-severe UC without increasing the overall risk of adverse events in short-term trials. These findings support the clinical utility of JAK inhibitors in UC management, while highlighting the need for long-term studies to better characterize rare and delayed safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048637","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:04:16Z","timestamp":1778745856000},"page":"e48637","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis"],"prefix":"10.1097","volume":"105","author":[{"given":"Qingqing","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Jiashan County Second People\u2019s Hospital, Jiashan County, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1286-5947","authenticated-orcid":false,"given":"Yuerong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang City, Hubei Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","article-title":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments.","volume":"45","author":"Wangchuk","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"R2-20260805","first-page":"406","article-title":"Ulcerative colitis: rapid evidence review.","volume":"105","author":"Adams","year":"2022","journal-title":"Am Fam Physician"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review.","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review.","volume":"31","author":"Damianos","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R5-20260805","doi-asserted-by":"crossref","first-page":"111229","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: a systematic review and meta-analysis of RCT and real-world observational studies.","volume":"126","author":"Zheng","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/ph18050740","article-title":"State-of-the-art evidence for clinical outcomes and therapeutic implications of janus kinase inhibitors in moderate-to-severe ulcerative colitis: a narrative review.","volume":"18","author":"Choi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12876-025-03627-2","article-title":"Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysisof randomized controlled trials.","volume":"25","author":"Elainein","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial.","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R12-20260805","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis.","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cpt.2601","article-title":"Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: results from phase II and phase III induction and maintenance studies.","volume":"112","author":"Mukherjee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5217\/ir.2021.00143","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b\/3 SELECTION trial.","volume":"21","author":"Hibi","year":"2023","journal-title":"Intest Res"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ueg2.12686","article-title":"Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: a post hoc analysis from the SELECTION study.","volume":"12","author":"Schreiber","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12876-022-02508-2","article-title":"Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.","volume":"23","author":"Lee","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective real-world experience.","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science.","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis.","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis.","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological association evidence synthesis.","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of janus kinase inhibitors in inflammatory bowel diseases.","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.3390\/jcm13237186","article-title":"Efficacy and safety of janus kinase-inhibitors in ulcerative colitis.","volume":"13","author":"Neri","year":"2024","journal-title":"J Clin Med"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.07.008","article-title":"Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease.","volume":"79","author":"Chen","year":"2024","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:02:37Z","timestamp":1785945757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048637","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"2026-02-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}